ImmuPharma PLC IMM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- GBX 2.14
- Day Range
- GBX 2.11–2.28
- 52-Week Range
- GBX 0.82–3.80
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 891.18 Mil
- Volume/Avg
- 604,698 / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 100.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.immupharma.co.uk
Valuation
|
Metric
|
IMM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.11 |
Price/Sales | 100.00 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMM
|
|---|---|
Quick Ratio | 0.99 |
Current Ratio | 1.17 |
Interest Coverage | — |
Quick Ratio
IMM
Profitability
|
Metric
|
IMM
|
|---|---|
Return on Assets (Normalized) | −84.58% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −148.76% |
Return on Assets
IMM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rmdfhqzqb | Crcmn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kshjrvcp | Lyhjht | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bpvlttpps | Sjwkr | $97.8 Bil | |
MRNA
| Moderna Inc | Sdfdnnsp | Rqzbs | $41.3 Bil | |
ARGX
| argenx SE ADR | Zzwzwmzm | Lzh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vtlhxvv | Ktx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Chsggbq | Zghlgc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rshhjtc | Fmhchy | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tyrnsmpjyh | Rgbyf | $12.5 Bil | |
INCY
| Incyte Corp | Tcqqdjbm | Wwcltf | $11.6 Bil |